Research and Evaluation

University Teaching Hospital: A cost minimization analysis of intravenous or subcutaneous trastuzumab treatment in patients with HER2-positive breast cancer in Ireland.

Leading Edge Group was asked to compare and contrast both trastuzumab SC and IV treatment pathways in two large Irish University teaching hospitals and assess which route of administration is more cost-effective and results in greater active healthcare professional (HCP) time savings.

On average, the total HCP time saved per trastuzumab SC treatment cycle relative to trastuzumab IV treatment cycle was 59.21 minutes. Time savings in favour of trastuzumab SC resulted from quicker drug reconstitution, no IV catheter installation and removal, and less HCP monitoring. Over a full treatment course of 17 cycles, average HCP time saved accumulates to 16.78 hours with a total estimated direct cost saving of €1,609.99. Loss of productivity for patients receiving trastuzumab IV (2.15 days) was greater than that of trastuzumab SC (0.60 days) for a full treatment course.

Related Case Studies

Reduced Waiting Times for Blood Donors

The Challenge Leading Edge Group was engaged to review this client’s clinic operations with the…

Improved Food and Nutrition Services

The Challenge This company is the governing commercial body of a number of Ontario-based hospitals.…

Marketing Office
Lean Marketing to Grow Sales

The organization required a significant growth.

Improved Competitiveness in Utilities

We used Lean to meet the client’s strategic and operational objectives

Contact Us

Please call or email us with any queries regarding our Lean Belt training programs.

Oceania - Australia

LEI Group Australia
1/76 Heller St
VIC 3055

Tel: + 61 (03) 9854 6136


Europe - Ireland

Charter House Cobh,
Co. Cork,
P24 R960

Tel: +353 (21) 4855863


North America - Canada

60 St. Clair Avenue East Suite 805,
Toronto, ON,
M4T 1N5,

Tel: +1 (416) 637 5074